Serzone Labeling Change Suggests Second-Line Use; Generics Affected
Executive Summary
Labeling for generic versions of Bristol-Myers Squibb's Serzone will encourage second-line use due to an increased risk of hepatotoxicity with the antidepressant
You may also be interested in...
Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out
Eight out of 10 antidepressant manufacturers asked by FDA to include a class warning in labeling on suicide risks have complied with the agency's request
Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?
Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14
Public Citizen Wants Serzone Pulled; No “Unique” Benefit To Offset Risk
Bristol-Myers Squibb's Serzone offers "no unique therapeutic benefit" to justify continued marketing in light of liver toxicity concerns, Public Citizen maintains in a March 6 petition to FDA